Inovio Pharmaceuticals (INO) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

INO Inovio Pharmaceuticals

Watchlist

8.7200
+0.1300+1.51%

Trading Aug 8 15:55 ET

225.94MMarket Cap-1582P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Inovio Pharmaceuticals Q2 24 Earnings Conference Call At 4:30 PM ET
RTTNews55minutes ago
Express News | Africa CDC Plans To Declare Regional Mpox Outbreak An Emergency
BenzingaAug 8 11:45 ET
Inovio Pharmaceuticals Q2 2024 Earnings Preview
Seeking AlphaAug 7 17:25 ET
'WHO Warns On Deadlier Strain Of Mpox' - Axios
BenzingaAug 5 12:09 ET
Express News | Inovio Receives Advanced Therapy Medicinal Product Certificate From European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate Ino-3107
ReutersJul 25 16:05 ET
INOVIO to Report Second Quarter 2024 Financial Results on August 8, 2024
PR NewswireJul 25 08:00 ET

Comments

Trytosaveabit

Jul 25 15:09

Update

$Inovio Pharmaceuticals (INO.US)$ Reuters· 3 mins ago
Inovio Receives Advanced Therapy Medicinal Product Certificate From European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate Ino-3107

Trytosaveabit

Jul 11 14:04

$Inovio Pharmaceuticals (INO.US)$ Pretty chart! I guess nobody with me? Hehehe

Trytosaveabit

Jul 11 12:18

My post in May wasn’t for this exact info! But it was watch for info on this drug! Hehehe. Just got some PR from another country! Hehehe

$Inovio Pharmaceuticals (INO.US)$ Company Announced That INO-3107, Has Been Designated an Innovative Medicine as Part of the U.K.'s Innovative Licensing and Access Pathway

Trytosaveabit

May 13 15:24

Make note of dates upcoming!

$Inovio Pharmaceuticals (INO.US)$ INOVIO Reports First Quarter 2024 Financial Results and Recent Business Highlights
• BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgicaltreatment for recurrent respiratory papillomatosis (RRP)
• Planning initiation of confirmatory trial for INO-3107 based on FDA feedback
• Advancing plans for Phase 3 trial of INO-3112 in combination with LOQTORZITM ...

Trytosaveabit

Apr 15 17:41

Ouch! Hehehe

$Inovio Pharmaceuticals (INO.US)$ Inovio Pharmaceuticals Inc - Pricing of an Underwritten Offering of 2.5 Mln Shares of Its Common Stock at an Offering Price of $7.693 per Share

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

INO Inovio Pharmaceuticals

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target